SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as investors digest recent financial results, with community chatter focused on valuation concerns after a significant run-up. While some bulls remain optimistic about the company's AI prospects and long-term growth, bears point to a high P/E ratio and potential market correction. News of a major investor taking a short position is also contributing to the conversation.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer ($PFE) is trending due to significant trading volume and speculation around potential acquisitions and earnings. Community discussions revolve around Michael Burry's call option positions and Pfizer's ongoing legal battles with Novo Nordisk over Metsera. Some traders anticipate a breakout post-earnings, while others remain skeptical, citing past performance and heavy debt.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is trending as investors discuss recent coverage from Stifel and JPMorgan, highlighting the company's potential in lunar infrastructure and space investments amid rising competition with China. The community is weighing the significance of new contracts and upcoming milestones, including the LTV contract and IM-3 mission, while also debating the stock's volatility and short interest.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending due to positive earnings reports and increasing discussion around its partnerships, especially regarding autonomous vehicle technology with companies like NVIDIA and Lucid. The community is actively discussing the potential for robotaxis and the impact on Uber's future profitability, though some express frustration with the stock's price action despite positive news. Some traders are wary of a potential downside setup, while others are aggressively buying calls in anticipation of a significant move upwards leading up to earnings.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending due to a sharp decline following confirmatory trial results for its PMO therapies; while the trial missed its primary endpoint, the company highlights COVID-related impacts and plans to discuss a path to traditional approval with the FDA. The community is debating the significance of the trial results, the future of PMO therapies, and the potential impact on the company's valuation, with some viewing the sell-off as an overreaction and a buying opportunity given Sarepta's revenue and pipeline.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending amid speculation about privacy coins and potential rotation from Bitcoin, with community members pointing to its limited supply and privacy features. Some traders are highlighting ZEC's strong performance relative to other cryptocurrencies and anticipating further gains, while others caution about overbought conditions and potential pullbacks. Discussions include potential price targets, comparisons to Bitcoin, and the upcoming anniversary catalyst.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegian Cruise Line is trending due to a mixed earnings report, beating EPS expectations but falling slightly short on revenue, sparking debate among investors about its valuation. While the company raised its 2025 adjusted EPS guidance and highlighted record revenue, community sentiment is divided, with some questioning the market's negative reaction and others pointing to potential overvaluation or broader market concerns. Community members are also discussing call/put walls and potential market manipulation.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify is trending due to a mixed reaction to earnings, initially dropping on EPS and sales misses despite subscriber growth. The community is debating whether the dip presents a buying opportunity, while analysts are adjusting price targets and highlighting both the potential and the risks around valuation and future growth. Commentary suggests a possible short squeeze is in play, but also concern about overall market weakness affecting SPOT.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amid discussions about its upcoming earnings report and potential partnerships, particularly with Novo Nordisk ($NVO). Community members are debating the company's growth prospects, with some highlighting its expansion into new markets and others expressing concern over profitability and insider selling. Analyst ratings are mixed, with some firms setting high price targets while others have a more cautious outlook.

Hut 8 Corp. operates as a Bitcoin miner that focuses on mining. It provides digital asset mining, hosting, and managed infrastructure operation services. The company was founded on January 27, 2023 and is headquartered in Miami, FL.

Hut 8 Corp

Hut 8 Corp is trending due to strong earnings reports and discussions around its transition into AI infrastructure, sparking bullish sentiment. The community is actively debating the company's future prospects in AI and HPC, as well as potential hyperscaler deals. Some investors are comparing HUT to other miners and AI-focused companies, while also considering the impact of Bitcoin's price on its valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arcus Biosciences (RCUS) Soars 8.5%: Is Further Upside Left in the Stock?

Arcus Biosciences (RCUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Wall Street Analysts Believe Ascendis Pharma (ASND) Could Rally 29.83%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 29.8% in Ascendis Pharma (ASND). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

U.S.-listed shares of Ascendis Pharma climbed more than 7% in Thursday’s premarket session, setting the stage for their best open since early January.Late on Wednesday, the company reported better-than-expected fourth-quarter results and announced a share repurchase program.The Danish biopharma company posted Q4 revenue of €173.92 million ($180.6 million), up from €137.7 million a year ago, while its loss per share narrowed to €0.64 from €1.53.&nbsp;CEO Jan Mikkelsen said the company is “positioned to continue strong revenue growth in 2025 and beyond,” citing Yorvipath’s early U.S. momentum and SkyTROFA’s leadership in the domestic growth hormone market.&nbsp;Ascendis also confirmed plans to submit regulatory filings for TransCon CNP as a treatment for children with achondroplasia.The board also authorized up to $18.25 million for repurchases of its American depository receipt shares.&nbsp;On Stocktwits, message volume for Ascendis spiked, with several posts indicating optimism over the guidance and Yorvipath’s growth.<stembedurl>https://stocktwits.com/Pika_Capital/message/604018998</stembedurl><stembedurl>https://stocktwits.com/CrispDry/message/603879227</stembedurl>BofA Securities on Thursday lowered its price target on Ascendis shares to $192 from $203 while maintaining a ‘Buy’ rating.&nbsp;The firm adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp, but reiterated Ascendis as a “top pick for 2025” with projected peak sales of €2.9 billion.Yorvipath recently became the only approved U.S. treatment for hypoparathyroidism after Takeda discontinued Natpara production due to supply issues.Despite the day’s gains, Ascendis shares remain down over 10% in the past year and trade about 54% below the average analyst target of $193.49, according to Koyfin data.&nbsp;&nbsp;The company’s stock has a short interest of 5.4%.(1 Euro=$1.04)For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ascendis Pharma Eyes Best Open In A Month After Q4 Print, But BofA Cuts Price Target: Retail Gets Buzzing

The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp.

Equity

The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp.


Ascendis Pharma A/S (NASDAQ:ASND) Given New $167.00 Price Target at JPMorgan Chase & Co.

Ascendis Pharma A/S (NASDAQ:ASND - Free Report) had its target price boosted by JPMorgan Chase & Co. from $165.00 to $167.00 in a research note issued to investors on Tuesday morning, Benzinga...

Ascendis Pharma A/S (NASDAQ:ASND) Given "Overweight" Rating at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in a report published on Monday morning, Benzinga reports. Cantor Fitzgerald...

Ascendis Pharma A/S (ASND, $151.98) Moving Average Convergence Divergence (MACD) Histogram turned positive on April 1, 2024

This is a Bullish indicator signaling ASND's price could rise from here. Traders may explore going long the stock or buying call options...

Ascendis Pharma A/S (ASND, $151.98) Stochastic Oscillator left the overbought zone on April 01, 2024

This is a signal that ASND's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

Values First Advisors Inc. Lowers Position in Ascendis Pharma A/S (NASDAQ:ASND)

Values First Advisors Inc. reduced its stake in Ascendis Pharma A/S (NASDAQ:ASND  Free Report) by 23.4% in the fourth quarter, according to its most recent filing with the Securities and...

Ascendis Pharma A/S (ASND, $148.44) Stochastic Oscillator left the oversold zone on March 27, 2024

This is a signal that ASND's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

1,616 Shares in Ascendis Pharma A/S (NASDAQ:ASND) Purchased by Legato Capital Management LLC

Legato Capital Management LLC purchased a new stake in Ascendis Pharma A/S (NASDAQ:ASND  Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities...

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau on September 21, 2006 and is headquartered in Hellerup, Denmark.

Ascendis Pharma A/S - ADR

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.28	--	--	N/A
Q2 '25	-$1.51	-$0.94	37.51%	BEAT
Q1 '25	-$1.67	-$1.84	-10.33%	MISSED
Q4 '24	-$0.98	-$0.72	25.80%	BEAT
Q3 '24	-$1.70	-$1.78	-4.65%	MISSED

ASND
Ascendis Pharma

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest ASND News

ASNDAscendis Pharma